Skip to content

A prospective randomized double-blind placebo-controlled parallel-group study of Zhihuang Xiaoyu Zhitong plaster in the treatment of acute lateral ankle ligament sprains

A prospective randomized double-blind placebo-controlled parallel-group study of Zhihuang Xiaoyu Zhitong plaster in the treatment of acute lateral ankle ligament sprains

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001458
Enrollment
Unknown
Registered
2025-07-21
Start date
2025-01-22
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lateral ankle ligament sprains

Interventions

Treatment Group:Zhihuang Xiaoyu Zhitong plaster

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Meeting both Traditional Chinese Medicine (TCM) and Western medicine diagnostic criteria; 2.Musculoskeletal ultrasound or MRI indicating grade I or II injury of the anterior talofibular ligament (ATFL); 3.Onset of injury within =2 days; 4.Age between 18 and 65 years (inclusive) regardless of sex; 5.No prior use of medications for acute closed soft tissue injuries; 6.Signed informed consent form and commitment to comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Presence of infection at the affected area or open wounds at the injury site; 2. Injuries involving two or more anatomical sites; 3. Pre-existing skin conditions at the injury site such as exudative dermatitis eczema infectious skin diseases burns or trauma; 4. Women who are pregnant breastfeeding or planning to become pregnant; 5. Use of medications with properties of promoting blood circulation reducing swelling and pain or relaxing tendons and activating collaterals within 7 days prior to enrollment; 6. Known allergies or hypersensitivity to the investigational drug; 7. Severe comorbidities involving the cardiovascular cerebrovascular hematologic gastrointestinal respiratory neurologic or endocrine systems; 8. Participation in other clinical trials within the past 3 months; 9. Any other condition deemed unsuitable for study participation by the investigators.

Design outcomes

Primary

MeasureTime frame
VAS Score;

Secondary

MeasureTime frame
range of motion (ROM);AOFAS Ankle-Hindfoot Score;Ankle musculoskeletal ultrasound;Foot and Ankle Ability Measure (FAAM);swelling degree;Traditional Chinese Medicine syndrome score;

Countries

China

Contacts

Public ContactRuoyu Yao

Longhua hospital shanghai university of traditional chinese medicine

842208790@qq.com+86 21 6438 5700

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026